InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 26 April 2022

This phase I/II study is trying to determine the appropriate dosing of a targeted therapy (AZD4573) alone, and then evaluate how effective it is when combined with another targeted therapy (acalabrutinib), in people with advanced blood cancersA Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies

Clinical summary


This is a non-randomised trial that has two modules, each with two parts. In Module 1 Part A, participants will receive ascending doses of AZD4573 (administered intravenously [via IV]) once weekly, in combination with oral, twice daily doses of acalabrutinib. Part A will have three different cohorts, each with different target dose levels of AZD4573. The primary objective of Part A is to determine the maximum tolerated dose for Part B. In Module 1 Part B, participants will receive AZD4573 at the dose level determined in Part A. Module 2 Part A has two phases. In Phase 1, participants will receive AZD4573 alone (administered via IV once weekly). In Phase 2, participants will receive AZD4573 (administered via IV once weekly) in combination with acalabrutinib (orally, twice daily). Module 2 Part B will be determined based on the data that emerges from Part A.


This trial is treating patients with advanced blood cancers, including Diffuse large B-cell lymphoma, Marginal zone lymphoma, Germinal Centre B-cell lymphoma, non-GCB Diffuse large B-cell lymphoma and Mantle Cell Lymphoma.


Blood Cancers Blood


People18 - 130



More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor


Scientific Title

A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies



  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.


  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.